Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
eUpdate – Early and Locally Advanced Non-Small-Cell LungCancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell LungCancer Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements: , , , , , Search eUpdate – Early and Locally Advanced Non-Small-Cell LungCancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell LungCancer (NSCLC) Treatment (...) cancer (NSCLC) who have not progressed following chemoradiotherapy whose tumours express programmed death-ligand 1 (PD-L1) on ≥1% of tumour cells, although the latter was a post hoc subgroup analysis. The recommendation is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor durvalumab, commenced 1–42 days post chemoradiotherapy, improved both progression-free survival [PFS; median PFS 16.8 versus 5.6 months; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.42–0.65, P <0.0001
. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 212 2 Information about lorlatinib Information about lorlatinib Marketing authorisation indication Marketing authorisation indication 2.1 Lorlatinib (Lorviqua, Pfizer) as monotherapy is indicated for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non- small cell lungcancer (NSCLC) whose disease has progressed after: • alectinib or ceritinib as the first ALK (...) that there was a significant unmet need for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lungcancer (NSCLC), even though 4 ALK tyrosine kinase inhibitor (TKI) treatments are available. The committee noted that neither crizotinib nor ceritinib are preferred for untreated disease since the availability of alectinib. Brigatinib has been approved for previously treated disease only after crizotinib. If alectinib's treatment effect wanes the only current option is chemotherapy. ALK TKI treatments
, which can hinder early diagnosis and treatment. 4, 5 Lungcancer presentations can also be complex, due to co-morbidities or plausible alternative diagnoses. 6 Lungcancer symptoms can present in a similar manner to other conditions such as chronic obstructive pulmonary disease (COPD), chronic heart failure and coronary heart disease. 7 Therefore, it is important to increase awareness of lungcancer symptoms and risk factors, and to provide all health professionals with the most recent evidence (...) with symptoms or signs consistent with lungcancer. The Guide does not provide advice on the following: • adults with mesothelioma • adults with lung metastases arising from primary cancer originating outside the lung • children (younger than 18 years) with lungcancer • adults with rare lungtumours • adults with benign lungtumours, and • adults being screened for lungcancer. For more information on the potential role of screening for asymptomatic patients, visit Cancer Australia’s lungcancer screening
The association of lungcancer with smoking can lead to lungcancer patients feeling stigmatised, contributing to delays in help-seeking for symptoms 4,5 and psychological distress. 6 Risk factors for lungcancer Lifestyle factors - current or former tobacco smoking Environmental or occupational factors - passive smoking - occupational exposures e.g. radon, asbestos, diesel exhaust, silica - air pollution Personal factors - increasing age - family history of lungcancer - chronic lungdisease e.g. chronic (...) obstructive pulmonary disease (COPD), pulmonary fibrosis - personal history of cancer e.g. lungcancer, head and neck cancer, bladder cancer Symptoms and signs of lungcancer Symptoms can present in a similar manner to other conditions such as COPD, chronic heart failure and coronary heart disease. 7 Please refer to the flow chart overleaf for symptoms and signs of lungcancer, recommended investigations and referrals, and timeframes for referral. 80 90 100 70 60 50 40 30 20 10 Stage at diagnosis and 5
screening, defer surveillance imaging of lung nodules, and minimize nonurgent interventions during the evaluation of lung nodules and stage I non-small cell lungcancer. INTERPRETATION: There was consensus that during the COVID-19 pandemic, it is appro- priatetodeferenrollmentinlungcancerscreeningandmodifytheevaluationoflungnodules ABBREVIATIONS: CDC = Centers for Disease Control and Prevention; COVID-19 = coronavirus disease 19; Lung-RADS = Lung CT Screening Reporting and Data System; pCA = probability (...) : consensus statement; COVID-19; lungcancer screening; lung nodule In some parts of the world, the coronavirus disease 2019 (COVID-19) pandemic has stressed the health- care systems close to or even past their breaking point. Rightfully, much of the attention to date has focused on the immediate needs of patients suffering from the disease, particularly those who are critically ill. The strain on health-care systems and the need to control the virus using containment (testing and isolating cases
irradiation for patients with small-cell lungcancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med . 1999 ; 341 : 476–484 | | | In ES disease, treatment typically involves chemotherapy alone x 9 Green, R.A., Humphrey, E., Close, H., and Patno, M.E. Alkylating agents in bronchogenic carcinoma. Am J Med . 1969 ; 46 : 516–525 | | | with or without PCI. x 10 Slotman, B., Faivre-Finn, C., Kramer, G. et al. Prophylactic cranial irradiation in extensive small (...) will commission a replacement or reaffirmation within 5-years of publication. 1. Introduction Small cell lungcancer (SCLC) is the second most common thoracic malignancy, representing approximately 13% of newly diagnosed lungcancers. x 1 in: N. Howlader, A. Noone, M. Krapcho, (Eds.) SEER Cancer Statistics Review . National Cancer Institute , Bethesda, MD ; 1975-2016 ( Available at: ) . ( Accessed November 22, 2019 ) SCLC is a particularly aggressive malignancy, with only about one-third of patients diagnosed
When indicated, use PET-CT prior to any staging EBUS and to identify alternative biopsy target. o In cases where there is a low risk of mediastinal disease, consider percutaneous lung biopsy or proceeding directly to treatment based on lungcancer probability (including the use of the Herder model) ? Omit contrast enhanced CT brain in clinical stage II lungcancer. ? Do not perform full lung function testing when the clinician and surgeon are happy with simple spirometry. ? Do not perform (...) chemotherapy for patients with mesothelioma to those with epithelioid tumours. 4. Information for Patients Please discuss with all patients undergoing diagnostic and staging tests or being referred for treatment that there are intense pressures on the NHS which may result in longer waits to undergo tests, see specialist clinicians and commence treatment. Please ensure they have contact details of their lungcancer specialist nurses (LCNS) or relevant team to discuss any concerns and seek support
EarlyCDT-Lung (Oncimmune) is a blood test that measures a group of 7 autoantibodies (p53, NYESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2) to tumour-associated antigens related to lungcancer. It helps early detection of lungcancer in people with high risk and allows differentiation of benign or malignant nodules. In the early stages of lungcancer, autoantibodies and tumour-associated antigens are produced as the body's immune system's response to cancer antigens. Blood levels of autoantibodies (...) . NICE's guideline on the diagnosis and management of lungcancer recommends sputum cytology for investigation in people with suspected lungcancer who have centrally placed nodules and are unable to tolerate bronchoscopy or invasive tests. A contrast-enhanced chest CT scan is recommended for further diagnosis and to stage the disease. The guideline recommends PET-CT as a first test after CT with a low probability of nodal malignancy (lymph nodes below 10 mm). MRI, endobronchial ultrasound-guided
: about 60% of NSCLCs are adenocarcinoma. Former or current smoking is often a causal factor in all forms of lungcancer. However, nonsmokers with lungcancer frequently have adenocarcinoma. This type of cancer is usually found on the outer parts of the lung. People with adenocarcinoma tend to have better survival than people with other types of lungcancer • Squamous cell (epidermoid) carcinoma: 25% to 30% of all NSCLCs are squamous cell carcinomas. Squamous cells are flat cells that line the inside (...) • Other subtypes: Less common NSCLC subtypes include adenosquamous carcinoma and sarcomatoid carcinoma The progression of cancer is divided into four stages; a higher number signifies more extensive disease. In stage 1, the cancer is confined to the original site within the lung and there is no sign of spread to lymph nodes (N0) or elsewhere (M0). In stage 2, the cancer has spread to lymph nodes within the lung (N1). In stage 3, the cancer has spread to lymph nodes in the middle of the chest
(Lorviqua ® ) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC) whose disease has progressed after: ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI In the relevant subgroup of a non-comparative (...) Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lungcancer (NSCLC) whose disease has progressed after: 1 ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI Dosing Information The recommended dose is 100mg lorlatinib taken orally once daily. Treatment with lorlatinib
Effect of lidocaine cream analgesia for chest drain tube removal after video-assisted thoracoscopic surgery for lungcancer: a randomized clinical trial Pain management makes an important contribution to good respiratory care and early recovery after thoracic surgery. Although the development of video-assisted thoracoscopic surgery (VATS) has led to improved patient outcomes, chest tube removal could be distressful experience for many patients. The aim of this trial was to test whether (...) the addition of lidocaine cream would have a signiﬁcant impact on the pain treatment during chest tube removal from patients who had undergone VATS for lung cancer.This clinical trial was a double-blind randomized study. Forty patients with histologically confirmed lungcancer amenable to lobectomy/segmentectomy were enrolled. All patients had standard perioperative care. Patients were randomly assigned to receive either epidural anesthesia plus placebo cream (placebo, Group P) or epidural anesthesia plus
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell LungCancer RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lungcancer (NSCLC).The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the other, with a primary end point (...) survival (PFS) rates were 32.1% and 23% and 18.3% and 13% (P = .055), respectively. Factors associated with improved OS on multivariable analysis were standard radiation dose, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart V5. The use of cetuximab conferred no survival benefit at the expense of increased toxicity. The prior signal of benefit in patients with higher H scores was no longer apparent. The progression rate within 1 month of treatment
LungCancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non-small-cell lungcancer (NSCLC) and SCLC.ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care, and advocacy experts to conduct a literature (...) for this guideline.Patients should undergo surveillance imaging for recurrence every 6 months for 2 years and then annually for detection of new primary lungcancers. Chest computed tomography imaging is the optimal imaging modality for surveillance. Fluorodeoxyglucose positron emission tomography/computed tomography imaging should not be used as a surveillance tool. Surveillance imaging may not be offered to patients who are clinically unsuitable for or unwilling to accept further treatment. Age should not preclude